Research Paper Volume 12, Issue 4 pp 3791—3806

Baicalin ameliorates neuropathology in repeated cerebral ischemia-reperfusion injury model mice by remodeling the gut microbiota

Figure 3. Oral baicalin supplementation suppresses decline in cognition, memory, and LTP in repeated cerebral ischemia-reperfusion model mice. (A) The chemical structure of baicalin. (BD) The preferential index of the (B) novel object recognition test after 1h training, (C) latency in the testing phase, and (D) time spent in the target quadrant of Morris water maze test of control, repeated cerebral ischemia-reperfusion (model group), and 50 mg/kg and 100 mg/kg baicalin-treated model group mice is shown. (E) The average population spike amplitudes from all control, model mice, and 50 mg/kg and 100 mg/kg baicalin-treated model group mice is shown. Note: *** denotes P<0.001 compared with the control mice using unpaired Student`s t-tests; # denotes P<0.05, ## denotes P<0.01, ### denotes P<0.001 in comparison with the model mice using one-way ANOVA analysis followed by Dunnett`s post hoc test or a two-way repeated-measures ANOVA with post-hoc Tukey multiple comparisons test. All the values are expressed as means ± S.D. Each group had 15 mice (n=15).